Improving Maternal heAlth by Reducing Malaria in African HIV Women
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Trial to evaluate the safety and efficacy of DHA-PPQ for Intermittent Preventive Treatment
(IPTp) in HIV-infected pregnant women receiving cotrimoxazole prophylaxis (CTXp) and
antiretroviral (ARV) drugs and using long lasting insecticide treated nets will be conducted
in Mozambique and Gabon where malaria and HIV infection are moderate to highly prevalent. In
addition, the possibility for a PK interaction between DHA-PPQ and ARV drugs will be assessed
in a sub-sample of participants. Women will receive ARV therapy according to national
guidelines and their infants will be followed until one year of age to evaluate the impact of
DHA-PPQ on MTCT-HIV.
Phase:
Phase 3
Details
Lead Sponsor:
Barcelona Institute for Global Health
Collaborators:
Bernhard Nocht Institute for Tropical Medicine Centre de Recherche Médicale de Lambaréné Centro de Investigação em Saúde de Manhiça Medical University of Vienna Medicines for Malaria Venture Universität Tübingen